Vor Historical Income Statement

VOR Stock

USD 0.87 0.02 2.25%

Historical analysis of Vor Biopharma income statement accounts such as Net Interest Income of 7.5 M, Interest Income of 7.5 M, Depreciation And Amortization of 3.4 M or Interest Expense of 987.4 K can show how well Vor Biopharma performed in making a profits. Evaluating Vor Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vor Biopharma's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Vor Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vor Biopharma is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

About Vor Income Statement Analysis

Vor Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vor Biopharma shareholders. The income statement also shows Vor investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Vor Biopharma Income Statement Chart

At this time, Vor Biopharma's Net Interest Income is relatively stable compared to the past year. As of 12/25/2024, Interest Income is likely to grow to about 7.5 M, while Interest Expense is likely to drop slightly above 987.4 K.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vor Biopharma. It is also known as Vor Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Vor Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vor Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.At this time, Vor Biopharma's Net Interest Income is relatively stable compared to the past year. As of 12/25/2024, Interest Income is likely to grow to about 7.5 M, while Interest Expense is likely to drop slightly above 987.4 K.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.4M	2.5M	3.2M	3.4M
Total Operating Expenses	69.0M	93.4M	126.0M	63.3M

Reconciled Depreciation Total Operating Expenses

Vor Biopharma income statement Correlations

	Net Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Non Operating Income Net Other	Selling And Marketing Expenses
Net Interest Income		0.51	0.29	0.75	0.79	-0.91	-0.89	-0.88	0.94	-0.89	0.79	0.93	-0.89	0.99	-0.9	-0.67	-0.52	0.54	0.8	-0.92
Depreciation And Amortization	0.51		0.43	0.89	0.84	-0.8	-0.82	-0.84	0.76	-0.82	0.84	0.79	-0.82	0.44	-0.81	-0.62	-1.0	1.0	0.77	-0.29
Interest Expense	0.29	0.43		0.41	0.42	-0.36	-0.36	-0.37	0.34	-0.36	0.42	0.41	-0.36	0.31	-0.36	-0.66	-0.44	0.43	0.46	-0.17
Selling General Administrative	0.75	0.89	0.41		0.99	-0.95	-0.96	-0.96	0.92	-0.96	0.99	0.91	-0.95	0.69	-0.95	-0.59	-0.89	0.89	0.86	-0.49
Other Operating Expenses	0.79	0.84	0.42	0.99		-0.95	-0.96	-0.96	0.92	-0.96	1.0	0.92	-0.96	0.73	-0.96	-0.61	-0.84	0.84	0.88	-0.52
Operating Income	-0.91	-0.8	-0.36	-0.95	-0.95		1.0	1.0	-1.0	1.0	-0.95	-0.99	1.0	-0.86	1.0	0.67	0.81	-0.82	-0.86	0.74
Net Income From Continuing Ops	-0.89	-0.82	-0.36	-0.96	-0.96	1.0		1.0	-0.99	1.0	-0.96	-0.99	1.0	-0.84	1.0	0.66	0.83	-0.84	-0.85	0.71
Ebit	-0.88	-0.84	-0.37	-0.96	-0.96	1.0	1.0		-0.99	1.0	-0.96	-0.99	1.0	-0.83	1.0	0.66	0.84	-0.86	-0.86	0.7
Research Development	0.94	0.76	0.34	0.92	0.92	-1.0	-0.99	-0.99		-0.99	0.92	0.99	-0.99	0.9	-0.99	-0.67	-0.77	0.78	0.84	-0.79
Ebitda	-0.89	-0.82	-0.36	-0.96	-0.96	1.0	1.0	1.0	-0.99		-0.96	-0.99	1.0	-0.84	1.0	0.66	0.83	-0.84	-0.85	0.71
Total Operating Expenses	0.79	0.84	0.42	0.99	1.0	-0.95	-0.96	-0.96	0.92	-0.96		0.92	-0.96	0.73	-0.96	-0.61	-0.84	0.84	0.88	-0.52
Reconciled Depreciation	0.93	0.79	0.41	0.91	0.92	-0.99	-0.99	-0.99	0.99	-0.99	0.92		-0.99	0.89	-0.99	-0.74	-0.8	0.81	0.88	-0.79
Income Before Tax	-0.89	-0.82	-0.36	-0.95	-0.96	1.0	1.0	1.0	-0.99	1.0	-0.96	-0.99		-0.85	1.0	0.66	0.82	-0.83	-0.85	0.72
Total Other Income Expense Net	0.99	0.44	0.31	0.69	0.73	-0.86	-0.84	-0.83	0.9	-0.84	0.73	0.89	-0.85		-0.85	-0.69	-0.45	0.47	0.77	-0.94
Net Income	-0.9	-0.81	-0.36	-0.95	-0.96	1.0	1.0	1.0	-0.99	1.0	-0.96	-0.99	1.0	-0.85		0.66	0.82	-0.83	-0.85	0.72
Income Tax Expense	-0.67	-0.62	-0.66	-0.59	-0.61	0.67	0.66	0.66	-0.67	0.66	-0.61	-0.74	0.66	-0.69	0.66		0.64	-0.65	-0.82	0.58
Gross Profit	-0.52	-1.0	-0.44	-0.89	-0.84	0.81	0.83	0.84	-0.77	0.83	-0.84	-0.8	0.82	-0.45	0.82	0.64		-1.0	-0.77	0.31
Cost Of Revenue	0.54	1.0	0.43	0.89	0.84	-0.82	-0.84	-0.86	0.78	-0.84	0.84	0.81	-0.83	0.47	-0.83	-0.65	-1.0		0.77	-0.34
Non Operating Income Net Other	0.8	0.77	0.46	0.86	0.88	-0.86	-0.85	-0.86	0.84	-0.85	0.88	0.88	-0.85	0.77	-0.85	-0.82	-0.77	0.77		-0.56
Selling And Marketing Expenses	-0.92	-0.29	-0.17	-0.49	-0.52	0.74	0.71	0.7	-0.79	0.71	-0.52	-0.79	0.72	-0.94	0.72	0.58	0.31	-0.34	-0.56

Click cells to compare fundamentals

Vor Biopharma Account Relationship Matchups

Vor Biopharma income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	(454K)	29K	119K	1.3M	7.1M	7.5M
Interest Income	154K	29K	119K	1.3M	7.1M	7.5M
Depreciation And Amortization	245K	1.4M	4.5M	9.0M	3.5M	3.4M
Interest Expense	608K	0.0	1.6M	1.3M	1.5M	987.4K
Selling General Administrative	4.2M	11.7M	21.5M	28.9M	31.7M	18.1M
Other Operating Expenses	10.4M	43.4M	69.0M	93.4M	126.0M	63.3M
Operating Income	(10.4M)	(43.4M)	(69.0M)	(93.4M)	(126.0M)	(119.7M)
Net Income From Continuing Ops	(10.8M)	(43.3M)	(68.9M)	(92.1M)	(115.5M)	(109.7M)
Ebit	(10.4M)	(43.3M)	(72.0M)	(99.9M)	(117.9M)	(112.0M)
Research Development	6.2M	31.6M	47.5M	64.6M	94.3M	99.0M
Ebitda	(10.2M)	(42.0M)	(67.6M)	(90.9M)	(114.4M)	(108.7M)
Total Operating Expenses	10.4M	43.4M	69.0M	93.4M	126.0M	63.3M
Reconciled Depreciation	91K	605K	1.4M	2.5M	3.2M	3.4M
Income Before Tax	(10.8M)	(43.3M)	(68.9M)	(92.1M)	(117.9M)	(112.0M)
Total Other Income Expense Net	(422K)	29K	119K	1.3M	8.2M	8.6M
Net Income Applicable To Common Shares	(12.6M)	(49.3M)	(70.1M)	(92.1M)	(82.9M)	(78.7M)
Net Income	(11.4M)	(43.3M)	(68.8M)	(90.8M)	(117.9M)	(112.0M)
Income Tax Expense	608K	427.7K	(119K)	(1.3M)	(1.2M)	(1.1M)

Pair Trading with Vor Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Vor Stock

0.7	VALN	Valneva SE ADR	Pair Corr
0.66	DTIL	Precision BioSciences	Pair Corr
0.63	DOMH	Dominari Holdings	Pair Corr
0.63	DRRX	Durect	Pair Corr
0.63	VIGL	Vigil Neuroscience	Pair Corr

The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.

The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vor Historical Income Statement

About Vor Income Statement Analysis

Vor Biopharma Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Vor Biopharma income statement Correlations

Vor Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vor Biopharma income statement Accounts

Pair Trading with Vor Biopharma

Moving against Vor Stock

Additional Tools for Vor Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Depreciation And Amortization
Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Cost Of Revenue	- 1.0	Gross Profit
Research Development	- 1.0	Operating Income
Gross Profit	- 1.0	Depreciation And Amortization
Net Income	- 0.99	Reconciled Depreciation
Income Before Tax	- 0.99	Reconciled Depreciation
Reconciled Depreciation	- 0.99	Ebitda